---
schema_version: "secwatch.filing_event.v1"
accession: "0001628280-24-034110"
form_type: "8-K"
ticker: "ARDX"
cik: "0001437402"
company_name: "ARDELYX, INC."
filed_at: "2024-08-01T23:59:59+00:00"
generated_at: "2026-05-31T13:44:50.640326+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Ardelyx Q2 total revenue $73.2M, driven by IBSRELA $35.4M and XPHOZAH $37.1M

## Summary
- IBSRELA Q2 net sales $35.4M, up ~25% QoQ; XPHOZAH Q2 net sales $37.1M, up from $15.2M in Q1 2024.
- Total revenue $73.2M vs $22.3M YoY; net loss narrowed to $16.5M ($0.07/sh) from $17.1M ($0.08/sh) YoY.
- FY 2024 IBSRELA revenue guidance unchanged at $140-150M; cash and investments $186M at quarter end.
- Filed lawsuit against CMS over ESRD PPS rule threatening XPHOZAH access; declined TDAPA application.
- SG&A expenses doubled to $64.7M primarily due to ongoing commercialization of both products.

## SEC filing metadata
- accession: 0001628280-24-034110
- form_type: 8-K
- ticker: ARDX
- cik: 0001437402
- company_name: ARDELYX, INC.
- filed_at: 2024-08-01T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1437402/000162828024034110/0001628280-24-034110-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1437402/000162828024034110/ardx-20240801.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001628280-24-034110
- JSON: https://secwatch.observer/filing/0001628280-24-034110.json
- Plain text: https://secwatch.observer/filing/0001628280-24-034110.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.